URAT1 inhibitor10 (Compound 23a) is a URAT1 inhibitor with an IC50 of 0.052 μM. It exhibits oral efficacy and low cytotoxicity. The compound demonstrates high selectivity for OAT1, with an IC50 of 9.17 μM.

URAT1 inhibitor 10, at a concentration of 5 μM for 30 minutes, inhibits OAT1 activity in MDCK-hOAT cells with an IC 50 of 9.17 μM. Additionally, after 24 hours, it exhibits moderate inhibition of IL-6 (IR = 25.6%) in RAW264.7 cells, which may alleviate symptoms related to MSU crystal-mediated inflammatory cytokines. Furthermore, URAT1 inhibitor 10 demonstrates low cytotoxicity in HepG2 cells, with an IC 50 greater than 64 μg/mL.

URAT1 inhibitor 10 (50 mg/kg; p.o.) exhibits favorable pharmacokinetic properties. Administered orally at 10 mg/kg once daily for seven days in a potassium oxonate-induced hyperuricemic mouse model, URAT1 inhibitor 10 significantly reduces serum uric acid (SUA) levels by 53.9%, comparable to the positive control Lesinurad given at the same dosage.